*Healthcare organizations can develop a value-based pricing strategy that benefits both patients and the organization. *The value-based pricing strategy of the Cleveland Clinic is based on five key components of value-relationship to cost, payment considerations, quality, market tolerance, and consistency. *Seven interrelated work streams can be used to align pricing inputs around the five components of value-based pricing.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Challenges in assessing national radiotherapy costs: application of the ESTRO-HERO model in Spain.
Front Public Health
January 2025
Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet Barcelona, Barcelona, Spain.
Background And Purpose: The aim was to estimate the cost of the external beam radiotherapy (EBRT) in public health care centers in Catalonia (Spain), according to the ESTRO-HERO costing model for 2018.
Materials And Methods: Personnel, equipment, and activity data from 2018 from the 11 RT centers were used, incorporating European mean values adapted to the Catalan context. Secondly, EBRT costs were estimated, incorporating 2023 fractionation technique and scheme usage percentages.
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs.
Pharmacoeconomics
December 2024
Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany.
Objectives: For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to the differential value a drug offers in each indication.
View Article and Find Full Text PDFA Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence.
Pharmacoeconomics
December 2024
Centre for Health Economics, University of York, York, UK.
Current approaches to the pricing and funding of new pharmaceuticals often focus on a one-time decision about a product for each clinical indication. This can result in multiple options being available to health systems without a clear signal about how to prioritise between them. This runs the risk that, as available treatments, evidence, and drug prices evolve, clinical and patient choices may not be aligned with the objective of allocating resources to promote population health.
View Article and Find Full Text PDFManaging Pharmaceutical Costs in Health Systems: A Review of Affordability, Accessibility and Sustainability Strategies.
J Mark Access Health Policy
December 2024
Department of Economics and Sustainable Development, Harokopio University, 17676 Athens, Greece;
Article Synopsis
- The paper reviews various cost containment policies aimed at controlling pharmaceutical spending by either regulating the industry or influencing consumer demand.
- A narrative literature review highlights that governments have adopted diverse strategies like cost-sharing, value-based pricing, and the promotion of generics, but their effectiveness varies between healthcare systems and can negatively affect patients.
- The conclusion emphasizes the need for thorough evaluation of these policies to ensure their success, as many lack strong evidence of cost-effectiveness and suggest that further research is essential to create tailored solutions that maintain affordability, fairness, and sustainability in healthcare.
Toward value-based care using cost mining: cost aggregation and visualization across the entire colorectal cancer patient pathway.
BMC Med Res Methodol
December 2024
Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
Background: The aim of this study is to develop a method we call "cost mining" to unravel cost variation and identify cost drivers by modelling integrated patient pathways from primary care to the palliative care setting. This approach fills an urgent need to quantify financial strains on healthcare systems, particularly for colorectal cancer, which is the most expensive cancer in Australia, and the second most expensive cancer globally.
Methods: We developed and published a customized algorithm that dynamically estimates and visualizes the mean, minimum, and total costs of care at the patient level, by aggregating activity-based healthcare system costs (e.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!